ACLXNMSHealthcare·Biotechnology#35 in industry

Arcellx, Inc.

Reports in 11d· 2026-05-07

+68.0% · 90d

$115.11

+0.07 (+0.07%)

News

(1)

April 2026

Apr 1, 20263 weeks agoSC TO-T/AHealthcare

Arcellx, Inc. — SC TO-T/A Filing

ACLXArcellx, Inc.

# 📄 What This Document Is This is a formal update (an "SC TO-T/A" filing) about a **tender offer**—a type of direct buyout offer. Gilead Sciences is trying to buy all the shares of a smaller company called Arcellx. This specific filing announces that Gilead is **extending the deadline** for Arcell

Read summaryView on SEC EDGAR

Key Data

Market Cap$6.73B

Open$115.03

Prev Close$115.03

Day Range$115.03 – $115.13

52W Range$47.86 – $115.13

Volume2,207,250

P/E (TTM)—

EPS$-4.07

Dividend Yield—

Beta0.25

Revenue Growth-89.20%

Price Target$112.85(-2.0%)

Next Earnings2026-05-07(11d)

Analyst Ratings

Hold18 analysts

Buy 0Hold 18Sell 0

About

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Healthcare · Biotechnology

209 employees

www.arcellx.com